This narrative review was designed for hospital boards, executives, integration leaders, clinical leaders, and policy audiences. Searches were completed on 12 August 2026 using PubMed/MEDLINE for peer-reviewed literature; Federal Trade Commission (FTC), Department of Justice, KFF, AHRQ, and health-system websites for policy and implementation evidence; and publisher and DOI pages for bibliographic verification. Table 1 summarizes the completed strategy and Supplementary Table S1 provides reproducible detail.

Sources were included when they addressed horizontal hospital mergers, acquisitions, vertical integration where transferable, market and price effects, clinical quality, workforce and culture, or post-acquisition implementation. Empirical studies and systematic reviews were prioritized, with organizational research used to interpret mechanisms not well captured in claims data. Selection was purposive, duplicate review and formal risk-of-bias scoring were not performed, and no effect estimates were pooled.

The synthesis used five questions: What value was promised? Which mechanisms could plausibly produce it? Which integration actions are required? What risks could offset it? How will leaders know whether value was realized? This structure separates transaction rationale from measured result.

The completed evidence-synthesis exhibits are presented in Table 2 and Table 3.

Hospital mergers occur within already concentrated markets. Economic reviews conclude that provider market concentration can increase prices and that quality effects are uncertain (5). Cooper and colleagues documented substantial variation in negotiated hospital prices and linked market structure to spending among privately insured patients (6). Research on cross-market acquisitions found price effects even without direct local overlap (7). Recent evidence similarly associated cross-market mergers, particularly serial acquisitions, with higher prices and no discernible improvement in selected mortality and readmission measures (8).

Boards and executives should not treat antitrust review as the only affordability safeguard. A transaction can be legally permissible and still produce financial harm to employers, patients, or public programs. The integration scorecard should include commercial price growth relative to market, patient out-of-pocket exposure, facility-fee changes, payer mix, uncompensated care, service availability, and financial-assistance use. Price and quality should be reported together.

Competition evidence also informs internal governance. If forecast returns depend mainly on higher negotiated prices rather than measurable efficiency or service improvement, the public value thesis is weak. Executives should distinguish revenue gained through market power from revenue gained through better access or performance. Independent board members should challenge assumptions about referral capture and closure of “duplicative” services when those changes reduce patient choice or increase travel.

Mergers may nevertheless preserve access where stand-alone viability is doubtful. That benefit should be made testable: which services would otherwise close, for how long will they be maintained, what capital will be invested, and how will access be measured? Commitments should survive leadership turnover and should include triggers for public or community notification if plans change.

Culture describes shared assumptions and norms about how work is done, whose voice counts, how conflict is handled, and what happens after failure. Mergers bring cultures into contact under unequal power. The acquiring organization’s language may dominate even when the stated aspiration is to “take the best of both.” Staff can interpret rapid replacement of local leaders or practices as evidence that prior contribution is not valued.

Research on mergers emphasizes the interaction of human integration and task integration (10). Sociocultural integration literature identifies cultural fit, dominance, tolerance, leadership style, trust, and the social climate of the transaction as relevant but not uniformly predictive (11). Health-care merger research has documented a slow and uneven convergence of hospital cultures, with new organizational fault lines appearing during change (12). These findings argue against reducing culture to an engagement survey or brand launch.

Cultural due diligence should occur before close where lawful and feasible. It can examine decision speed, hierarchy, speaking up, teamwork, performance management, physician relationships, community identity, and attitudes toward standardization. Data should be collected by site and professional group because senior-leader perceptions may differ from frontline experience.

Leaders should define a small number of observable integration behaviors. Examples include escalating safety concerns without retaliation, documenting decisions and rationale, involving affected teams before workflow change, resolving intersite conflict within a stated time, and recognizing local innovations. These are more actionable than values posters.

Psychological safety is particularly important during integration. Teams learn when members believe interpersonal risk is safe (13). Health-care status differences can inhibit speaking up, while inclusive leadership supports improvement behavior (14). Integration leaders should explicitly invite dissent, protect messengers, track issue closure, and distinguish constructive challenge from resistance. If bad news stops traveling upward, apparent integration progress may be dangerous.

A common EHR can improve information continuity and enterprise analytics, but conversion is a clinical transformation with known transition risk. Data mapping, order sets, medication lists, interfaces, patient identity, referral queues, portal access, and downtime procedures require validation. Leaders should preserve historical data access and define how unresolved records and duplicate identities are handled.

Technology integration should follow clinical design. Copying the acquirer’s build may propagate poor workflow; preserving every local customization defeats interoperability. A multidisciplinary governance process should classify content as evidence-based standard, required local variation, or legacy preference. Metrics should include usability, order errors, inbox burden, turnaround time, help requests, and safety events—not merely milestones met.

Operational integration should focus on end-to-end patient journeys. A centralized transfer center may increase access but overload the acquired site or redirect profitable cases away from it. Service-line consolidation may improve volume-outcome relationships but increase travel and reduce emergency backup. Supply standardization may lower price but create training or clinical preference risk. Each workstream needs patient, workforce, access, and financial balancing measures.

Vertical integration evidence offers a caution: organizational ownership does not automatically create clinical integration. A systematic review found mixed quality effects and little consistent efficiency or patient-centered improvement (16). Economic analysis similarly raises concerns about spending and market power (17). Executives should measure whether shared ownership changes care coordination, not assume it.

Merger evaluation should not rely only on the assumptions used to approve the transaction. Dafny’s econometric work demonstrated the importance—and difficulty—of identifying merger effects against an appropriate counterfactual (18). Later retrospective analyses found average price increases and heterogeneity across transactions, showing why aggregate synergy claims need transaction-specific testing (19). State-supervised certificates of public advantage illustrate that oversight design, durability, and enforceability affect whether claimed public benefits are protected (20).

Internal integration governance should therefore anticipate external questions. Directors should be able to explain why the transaction was necessary, which alternatives were considered, what access and quality commitments were made, what prices changed, which services moved, and whether the measured benefits exceeded cost and harm. Community-facing reporting should use stable definitions and disclose material changes in assumptions.

Policy commentary has long warned that consolidation can affect price, access, and quality through several pathways (21,22). Empirical hospital-quality research has also found heterogeneous effects rather than a universal gain (23). These sources support independent challenge rather than a presumption for or against every transaction. A board may use an external clinical reviewer, safety-culture assessment, independent actuary or economist, community advisory group, or post-close audit committee depending on the material risks.

Human integration deserves the same discipline as financial integration. Decades of merger research show persistent gaps between transaction rationale and realized performance and identify the need to study process, context, and implementation (24). Culture should be assessed as patterns of assumptions and behavior that develop over time, not as a list of declared values (25). Independent qualitative review can identify whether staff feel safe reporting integration defects, whether local expertise reaches enterprise decisions, and whether leadership actions match stated commitments.

Corrective authority must be real. If evidence shows worsening access, safety, workforce instability, or affordability, leaders should pause a workstream, restore a local process, add resources, revise a service-line plan, or renegotiate a commitment. Integration governance fails when milestones are treated as irreversible simply because contracts, executive reputations, or capital have been committed.

Post-close review should continue beyond the usual integration-office horizon. Price effects, service consolidation, workforce turnover, and referral shifts may emerge over several years. A three- to five-year evaluation should compare actual outcomes with the pre-close value thesis and a documented counterfactual. Lessons should inform future transactions, including a decision not to acquire when the organization lacks integration capacity.

Hospital mergers create the possibility of scale, investment, and coordinated care, but they do not automatically create value. The more consistent empirical effect is higher commercial price; average quality improvement is not established. A carefully executed full-integration model may improve outcomes in specific settings, but those results must be earned and demonstrated.

Boards should approve a testable public value thesis, establish pre-close baselines, protect clinical continuity and critical talent, define enterprise non-negotiables and local autonomy, and monitor culture and psychological safety. Integration leaders should sequence high-risk changes, validate data, make benefits net and auditable, and use stop-or-correct thresholds. Success is not a closed transaction or a unified logo. It is sustained improvement in quality, access, workforce stability, affordability, equity, and financial resilience.